Published in Blood Weekly, May 28th, 2009
The retrospective cohort study of 10,928 patients investigated the current real-world dosing patterns and associated ESA costs in an adult cancer chemotherapy population. The data showed that the cumulative ESA cost was $4,321 for patients receiving EPO vs. $6,089 for DARB...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.